To Örebro University

oru.seÖrebro universitets publikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
A narrative commentary about interoperability in medical devices and data used in diabetes therapy from an academic EU/UK/US perspective
Örebro universitet, Institutionen för medicinska vetenskaper.ORCID-id: 0000-0003-1025-1682
Department of Paediatrics, The Hospital of Halland Kungsbacka, Kungsbacka, Sweden; Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
Diabetes Research Centre, University of Leicester, Leicester, UK.
Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia; Department of Paediatric Endocrinology, Diabetes and Metabolic Diseases, University Children's Hospital, Ljubljana, Slovenia.
Vise andre og tillknytning
2024 (engelsk)Inngår i: Diabetologia, ISSN 0012-186X, E-ISSN 1432-0428, Vol. 67, nr 2, s. 236-245Artikkel, forskningsoversikt (Fagfellevurdert) Published
Abstract [en]

People living with diabetes have many medical devices available to assist with disease management. A critical aspect that must be considered is how systems for continuous glucose monitoring and insulin pumps communicate with each other and how the data generated by these devices can be downloaded, integrated, presented and used. Not only is interoperability associated with practical challenges, but also devices must adhere to all aspects of regulatory and legal frameworks. Key issues around interoperability in terms of data ownership, privacy and the limitations of interoperability include where the responsibility/liability for device and data interoperability lies and the need for standard data-sharing protocols to allow the seamless integration of data from different sources. There is a need for standardised protocols for the open and transparent handling of data and secure integration of data into electronic health records. Here, we discuss the current status of interoperability in medical devices and data used in diabetes therapy, as well as regulatory and legal issues surrounding both device and data interoperability, focusing on Europe (including the UK) and the USA. We also discuss a potential future landscape in which a clear and transparent framework for interoperability and data handling also fulfils the needs of people living with diabetes and healthcare professionals.

sted, utgiver, år, opplag, sider
Springer, 2024. Vol. 67, nr 2, s. 236-245
Emneord [en]
Big data, Diabetes therapy, Glucose monitoring, Insulin delivery systems, Interoperability, Medical devices, Review
HSV kategori
Identifikatorer
URN: urn:nbn:se:oru:diva-110009DOI: 10.1007/s00125-023-06049-5ISI: 001122367300001PubMedID: 38041737Scopus ID: 2-s2.0-85178455391OAI: oai:DiVA.org:oru-110009DiVA, id: diva2:1816561
Forskningsfinansiär
Örebro UniversityMedtronic, SwedenTilgjengelig fra: 2023-12-04 Laget: 2023-12-04 Sist oppdatert: 2024-03-22bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMedScopus

Person

Jendle, Johan

Søk i DiVA

Av forfatter/redaktør
Jendle, Johan
Av organisasjonen
I samme tidsskrift
Diabetologia

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 97 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf